NUCB2 and pancreatic adenocarcinoma: While CCDC88A, CCDC88C, and NUCB2 expression did not correlate with prognosis in PAAD patients (Figures 1A–C), low expression of NUCB1 was highly associated with lower patient survival rate (Figure 1C).